Pacira BioSciences, Inc. (PCRX)
| Market Cap | 999.04M -11.5% |
| Revenue (ttm) | 734.86M +4.6% |
| Net Income | 5.14M |
| EPS | 0.12 |
| Shares Out | 39.35M |
| PE Ratio | 213.05 |
| Forward PE | 8.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 370,490 |
| Open | 25.14 |
| Previous Close | 25.03 |
| Day's Range | 24.43 - 25.55 |
| 52-Week Range | 18.80 - 27.64 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 29.67 (+16.86%) |
| Earnings Date | Aug 4, 2026 |
About PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price target is $29.67, which is an increase of 16.86% from the latest price.
News
Pacira announces UnitedHealth provides separate reimbursement for Exparel
Pacira (PCRX) announced that UnitedHealthcare (UNH) now provides separate reimbursement for Exparel across outpatient settings, including hospital outpatient departments and ambulatory surgery centers...
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the in...
Pacira Zimmer to divest iovera degrees to Biomet for $70M upfront
Pacira (PCRX) announced the divestiture of iovera degrees to Zimmer Biomet (ZBH). The iovera degrees system is a FDA-cleared, drug-free medical device that relieves pain via cryoneurolysis-a process w...
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advanc...
20 growth stocks priced as value stocks
A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight fin...
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapi...
Pacira BioSciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is executing a 'five by 30' strategy, driving strong growth in non-opioid pain management with robust Q1 results and expanding market access. Key pipeline catalysts, strengthened IP, and disciplined capital allocation support long-term double-digit growth targets.
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warran...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Pacira BioSciences Transcript: Jefferies Global Healthcare Conference 2026
The company is executing a 5x30 growth strategy, expanding payer access and partnerships, and expects double-digit growth for EXPAREL. Key pipeline readouts, including PCRX-201 for knee OA, are anticipated by year-end, while robust IP and manufacturing complexity protect market position.
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change" BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- ...
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
First quarter 2026 revenue up 79.4% compared to the first quarter of 2025 First quarter 2026 gross profit increased 71.9% compared to the first quarter of 2025 First quarter same-store sales were up 7...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Glass Lewis recommends shareholders vote for Pacira director nominees
Pacira (PCRX) announced that leading independent proxy advisory firm Glass Lewis has recommended that Pacira stockholders vote “FOR” each of Pacira’s three director nominees and “AGAINST” all three of...
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees
BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain the...
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION
PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATE DOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AN...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees
Clarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE P...
Pacira study shows Exparel reduces opioid use and costs
Pacira (PCRX) BioSciences announced findings from a real-world study evaluating outcomes associated with the use of Exparel following outpatient total shoulder arthroplasty in Medicare Advantage patie...
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use BRISBANE, Calif., May 27, 2026 (GLOBE NE...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 27, 2026, providing details for shareholder voting and corporate governance matters.
Pacira issues statement on DOMA’s ‘misleading’ statements
Pacira (PCRX) BioSciences issued the following statement with important facts stockholders should know regarding Pacira’s intellectual property strategy, and DOMA Perpetual Capital Management’s recent...
Pacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property Strategy
Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
Purchase price of approximately $8.2 million The acquisition represents a continued expansion of PharmaCorp's footprint in Ontario SASKATOON, Saskatchewan, May 25, 2026 (GLOBE NEWSWIRE) -- PHARMACORP ...